Can Ivermectin, Mebendazole, Fenbendazole or Niclosamide Help Overcome Tagrisso Resistance? A 2026 Evidence Review

Medically Reviewed by: OneDayMD Editorial Team | Written by: Dr Frank Yap, MD | Last Updated: August 8, 2026

Can ivermectin, mebendazole, fenbendazole or niclosamide overcome Tagrisso resistance? These repurposed drugs have generated interest because some affect signaling pathways involved in cancer-cell survival and drug resistance. However, the current evidence does not establish any of them as clinically proven treatments for osimertinib-resistant EGFR-mutated lung cancer.

Tagrisso (osimertinib) is a third-generation EGFR tyrosine kinase inhibitor used extensively for EGFR-mutated non-small-cell lung cancer (NSCLC). Although osimertinib can produce prolonged disease control, acquired resistance eventually develops in most patients with advanced disease.

Key takeaway: The scientifically strongest approach to Tagrisso resistance is not to empirically add several repurposed drugs. It is to identify the resistance mechanism through molecular profiling and, when appropriate, tissue biopsy, and then match treatment to that mechanism.

Tagrisso Resistance Is Biologically Heterogeneous

Osimertinib resistance can develop through several distinct mechanisms. Some remain dependent on EGFR, while others allow the cancer to bypass EGFR altogether.

MET amplification or activation
Secondary EGFR mutations, including C797S
HER2 and AXL bypass signaling
KRAS/RAS/MAPK pathway activation
PI3K/AKT/mTOR activation
Wnt/β-catenin signaling
Epithelial-mesenchymal transition (EMT)
Small-cell or other histologic transformation
Metabolic and replication-stress adaptations

A 2026 clinical series found bypass signaling in 38% of sequenced cases, EGFR-dependent resistance in 10%, and histologic transformation in 5%, although nearly half had no identifiable mechanism.

This heterogeneity explains why a drug that appears promising against one resistance pathway may have little or no relevance to another.

Evidence Map: Repurposed Drugs vs. Tagrisso Resistance Mechanisms

The following evidence map separates biological plausibility from clinical evidence. A mechanistic connection should not be interpreted as proof that a drug works in patients.

Resistance mechanism	Ivermectin	Mebendazole	Fenbendazole	Niclosamide	Evidence interpretation
MET amplification	Theoretical / preclinical	Limited	Limited	Pathway rationale	MET-directed strategies have much stronger clinical rationale.
EGFR C797S	No convincing evidence	No convincing evidence	No convincing evidence	No convincing evidence	On-target resistance requires a mechanism-specific EGFR strategy.
Other EGFR mutations	No convincing evidence	No convincing evidence	No convincing evidence	No convincing evidence	No established ability to restore osimertinib binding.
KRAS/MAPK bypass	Preclinical	Preclinical	Preclinical	Preclinical	Biological overlap exists, but clinical resistance reversal has not been demonstrated.
PI3K/AKT/mTOR	Stronger preclinical rationale	Preclinical	Preclinical	Stronger preclinical rationale	One of the more interesting research areas, but not clinically validated.
Wnt/β-catenin	Preclinical interest	Preclinical	Preclinical	Preclinical interest	Niclosamide and ivermectin are particularly interesting research candidates.
AXL/EMT	Preclinical	Preclinical	Preclinical	Preclinical	Potential biological overlap; no established clinical role.
YAP/TEAD / phenotypic resistance	Preclinical	Limited	Limited	Preclinical	Interesting pathway hypothesis, not a proven treatment.
Small-cell transformation	No established role	No established role	No established role	No established role	Requires recognition of the transformed histology and appropriate treatment.
Metabolic / replication-stress resistance	Early research	Early research	Early research	Early research	Emerging research area; no established clinical application.

Evidence key: Stronger preclinical rationale = relatively interesting laboratory evidence; Preclinical = laboratory/mechanistic evidence; Limited = little directly relevant evidence. None of these categories represents proven clinical efficacy.

1. MET Amplification: Why It Matters

MET amplification is one of the best-established bypass mechanisms of acquired osimertinib resistance. The tumor can become less dependent on EGFR and use MET signaling to maintain downstream survival pathways.

This is where mechanism-based treatment is particularly important.

Although ivermectin and niclosamide have biological effects on multiple signaling pathways, there is currently no clinical evidence that either drug can replace a validated MET-directed strategy.

Bottom line: MET amplification should trigger consideration of an appropriate MET-targeted treatment or clinical trial—not an assumption that repurposed antiparasitic drugs will overcome resistance.

2. EGFR C797S: A Major On-Target Resistance Mechanism

C797S is fundamentally different from MET amplification. It changes the EGFR target itself and can prevent osimertinib from forming its normal covalent interaction with EGFR.

Consequently, suppressing downstream pathways with ivermectin, mebendazole, fenbendazole or niclosamide does not necessarily restore osimertinib binding.

Current evidence does not establish any of these four drugs as a treatment for C797S-mediated resistance.

3. PI3K/AKT/mTOR: The Most Interesting Repurposing Hypothesis

The PI3K/AKT/mTOR pathway regulates proliferation, survival and metabolism and can contribute to resistance to targeted therapy.

This is one of the areas where the repurposing hypothesis becomes more scientifically interesting.

Ivermectin: experimental studies have reported effects involving PI3K/AKT/mTOR signaling.
Mebendazole: has demonstrated experimental effects on multiple cancer-associated signaling pathways.
Fenbendazole: has laboratory evidence involving several cellular survival and metabolic processes.
Niclosamide: has broad experimental activity across several signaling networks.

These findings provide a rationale for laboratory research but do not prove that any of these drugs can reverse osimertinib resistance in humans.

4. KRAS/MAPK Bypass

Activation of the RAS/RAF/MAPK network can provide cancer cells with an alternative growth signal despite EGFR inhibition.

The four repurposed drugs have varying degrees of experimental interaction with intracellular signaling networks, but there is no prospective clinical evidence showing that any of them specifically reverses KRAS/MAPK-mediated osimertinib resistance.

5. Wnt/β-Catenin: An Interesting Research Target

Wnt/β-catenin signaling is associated with cancer-cell stemness, proliferation, differentiation and treatment resistance.

Niclosamide and ivermectin are particularly interesting from a research perspective because both have been investigated experimentally in relation to Wnt-related signaling.

This produces a testable hypothesis:

Could Wnt/β-catenin activation contribute to osimertinib resistance, and could a pathway-directed repurposed drug restore sensitivity?

At present, this remains a preclinical research question, not an established clinical treatment.

6. AXL and EMT

AXL signaling and epithelial-mesenchymal transition (EMT) are additional mechanisms associated with drug-tolerant and resistant cancer-cell states.

Because several repurposed drugs influence multiple signaling pathways, they may be worth studying in experimental models of AXL/EMT-associated resistance.

However, there is currently insufficient clinical evidence to recommend any of these four agents specifically for AXL/EMT-mediated osimertinib resistance.

7. Small-Cell Transformation: A Different Category of Resistance

Some EGFR-mutated lung adenocarcinomas can undergo small-cell or neuroendocrine transformation following EGFR-TKI treatment.

This is not simply a signaling pathway that can necessarily be blocked by adding another drug. It represents a fundamental change in tumor phenotype.

There is no established evidence that ivermectin, mebendazole, fenbendazole or niclosamide reverses small-cell transformation.

8. Emerging Metabolic and Replication-Stress Mechanisms

Research is increasingly identifying mechanisms beyond the traditional EGFR/MET framework. Recent work has investigated dNTP homeostasis, DNA replication stress and checkpoint signaling as potential vulnerabilities associated with osimertinib resistance.

These emerging findings demonstrate why resistance biology should not be reduced to a single pathway or a single repurposed drug.

They also provide opportunities for future research into rational combinations—but those combinations need to be tested systematically rather than inferred from isolated pathway observations.

Which Repurposed Drug Looks Most Interesting?

If the question is research priority rather than proven clinical efficacy, the four agents can be ranked approximately as follows:

1. Niclosamide
Broad multi-pathway activity and particularly interesting preclinical rationale involving several pathways relevant to resistance.

2. Ivermectin
Multiple experimental effects on cancer-cell signaling, survival and pathway regulation make it an interesting research candidate.

3. Mebendazole
Has plausible anticancer mechanisms but less direct evidence connecting it to osimertinib resistance mechanisms.

4. Fenbendazole
Interesting laboratory findings, but substantially weaker clinical evidence in this specific setting.

Important: this is a ranking of research interest, not a recommendation to use these drugs in patients.

Why Molecular Testing Should Come Before Adding Drugs

When an EGFR-mutated NSCLC progresses during Tagrisso treatment, the clinically important question is:

What resistance mechanism is driving the progression?

Depending on the clinical circumstances, oncologists may consider:

Liquid biopsy / circulating tumor DNA (ctDNA)
Tissue biopsy
Comprehensive next-generation sequencing
Assessment for histologic transformation
Clinical-trial enrollment

Tissue biopsy can be particularly important when transformation is suspected because a blood-based test may not reveal a change in histology.

Tagrisso + Ivermectin + Mebendazole/Fenbendazole: What Can Actually Be Claimed?

There is increasing interest in combinations of osimertinib with repurposed drugs. Case reports and anecdotal treatment experiences may generate useful hypotheses, but they cannot establish efficacy.

For example, if a patient receives:

osimertinib
ivermectin
mebendazole
fenbendazole
dietary or metabolic interventions

and subsequently experiences tumor shrinkage or stable disease, it is impossible from that observation alone to determine which intervention produced the effect.

The evidence hierarchy therefore remains:

Prospective randomized clinical trial
Prospective clinical trial
Well-designed observational study
Case series
Case report
Animal model
Cell-line/preclinical experiment
Mechanistic hypothesis

Most evidence supporting ivermectin, mebendazole, fenbendazole or niclosamide in this specific context currently sits toward the preclinical or mechanistic end of this hierarchy.

The Most Promising Future Strategy: Mechanism-Matched Combination Therapy

The future of EGFR-mutated lung cancer treatment may increasingly involve molecularly guided combinations.

For example:

MET amplification → EGFR + MET-directed strategies
EGFR on-target resistance → next-generation EGFR-directed approaches
PI3K/AKT/mTOR activation → pathway-directed experimental combinations
AXL/EMT → investigation of AXL/EMT-targeted strategies
Histologic transformation → treatment based on the new histology
Unknown resistance → broader molecular investigation and clinical-trial consideration

Repurposed drugs could eventually become components of such strategies if clinical trials demonstrate meaningful benefit. At present, that evidence is missing.

Bottom Line

Ivermectin, mebendazole, fenbendazole and niclosamide should currently be regarded as experimental research candidates—not proven methods of overcoming Tagrisso resistance.

Among the four, niclosamide and ivermectin have the most interesting multi-pathway research rationale, particularly around PI3K/AKT/mTOR and Wnt/β-catenin biology. Mebendazole and fenbendazole are more speculative in the specific context of osimertinib resistance.

But the most important clinical lesson is more fundamental:

Do not assume resistance is the same in every patient.

Identify the resistance mechanism first. Then match the treatment to the mechanism.

For a patient with EGFR-mutated Stage IV NSCLC progressing on Tagrisso, molecular profiling and appropriate tissue evaluation can provide substantially more actionable information than empirically adding multiple repurposed drugs.

Medical disclaimer: This article is an educational evidence review and is not medical advice. Ivermectin, mebendazole, fenbendazole and niclosamide are not established treatments for osimertinib resistance. They should not be substituted for approved cancer treatment or used to discontinue Tagrisso without the guidance of the treating oncology team.

Frequently Asked Questions

Is Tagrisso resistance common?

Yes. Acquired resistance is a major challenge in advanced EGFR-mutated NSCLC. Osimertinib can provide substantial disease control, but advanced cancers frequently eventually develop resistance.

What is the most important Tagrisso resistance mechanism?

There is no single mechanism responsible for all cases. MET amplification is an important bypass mechanism, while secondary EGFR mutations such as C797S represent important on-target resistance mechanisms.

Can ivermectin reverse Tagrisso resistance?

There is currently no clinical evidence demonstrating that ivermectin reverses osimertinib resistance. Its effects on several cancer-related pathways make it a subject for preclinical investigation.

Can mebendazole overcome osimertinib resistance?

No clinical evidence currently establishes mebendazole as a resistance-reversing treatment for EGFR-mutated NSCLC.

Can fenbendazole overcome Tagrisso resistance?

There is no convincing clinical evidence that fenbendazole overcomes osimertinib resistance. The evidence remains predominantly preclinical.

Is niclosamide more promising?

Niclosamide is an interesting research candidate because of its broad effects on cancer-associated signaling pathways. However, its ability to overcome osimertinib resistance has not been established in clinical trials.

What should happen when Tagrisso stops working?

The priority is to determine the cause of progression. Depending on the circumstances, liquid biopsy, tissue biopsy and comprehensive molecular profiling can identify actionable resistance mechanisms or histologic transformation.

References and Further Reading

Editorial conclusion: The most credible future strategy is unlikely to be a universal "Tagrisso resistance protocol." It is more likely to be precision combination therapy based on the molecular cause of resistance. Repurposed agents may eventually contribute to that strategy, but they need rigorous laboratory validation and prospective clinical trials before they can be considered established components of EGFR-resistant lung-cancer treatment.